NDUFC2-KCTD14: A Drug Target / Disease Biomarker (G100532726)

Target Name: NDUFC2-KCTD14

NCBI ID: G100532726

NDUFC2-KCTD14

NDUFC2-KCTD14: A Drug Target / Disease Biomarker

Native Domain-Driven Unit of the N-Acyl-L-Tryptophan Carboxylate Transporter 2 (NDUFC2) and K-Content Transmembrane Channels (KCTD14) as Potential Drug Targets

Natural products derived from microbial sources have always been a source of interest due to their unique biological properties and potential health benefits. One of the natural compounds that have gained significant attention in recent years is the non-coding RNA (ncRNA) NDUFC2, which has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

The N-Acyl-L-Tryptophan Carboxylate Transporter 2 (NDUFC2) is a transmembrane protein that plays a crucial role in the transport of L-tryptophan, an essential amino acid, in the cell. TheNDUFC2 gene has been shown to be involved in various cellular processes, including cell signaling, DNA replication, and stress response. In addition, studies have suggested that NDUFC2 may be involved in the regulation of inflammation and oxidative stress, which could make it an attractive target for drug development.

K-Content Transmembrane Channels (KCTD14) are a family of proteins that are characterized by their ability to transport small molecules, including ketones, across the cell membrane. These channels are involved in various physiological processes in the cell, including metabolism, neurotransmission, and signaling. recent studies have shown that KCTD14 are involved in the regulation of pain perception and neurotransmission, making them an attractive target for drug development in neuroscience.

The potential drug targets of NDUFC2 and KCTD14 are due to their unique functions and the various diseases that they are associated with. NDUFC2 has been shown to be involved in the regulation of cell signaling, which could make it an attractive target for drugs that target signaling pathways associated with cancer, neurodegenerative diseases, and metabolic disorders. Additionally, its involvement in the regulation of inflammation and oxidative stress could make it an attractive target for drugs that are effective in treating these conditions.

KCTD14 is involved in the regulation of various physiological processes in the cell, including metabolism, neurotransmission, and signaling. Its involvement in these processes makes it an attractive target for drugs that are effective in treating diseases associated with these processes, such as pain perception and neurotransmission.

The potential drug targets of NDUFC2 and KCTD14 are still under investigation, but their potential as drug targets is significant. The development of small molecules that can modulate the activity of these proteins may lead to the development of new treatments for a variety of diseases.

In conclusion, NDUFC2 and KCTD14 are unique proteins that play important roles in various cellular processes in the cell. Their potential as drug targets makes them attractive targets for the development of new treatments for a variety of diseases. Further research is needed to fully understand the functions of these proteins and to develop small molecules that can modulate their activity.

Protein Name: NDUFC2-KCTD14 Readthrough

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity)

The "NDUFC2-KCTD14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFC2-KCTD14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets